ArchiMed acquires neurodiagnostic devices provider Natus Medical
Natus shareholders received $33.50 in cash for each share of company common stock.

Natus shareholders received $33.50 in cash for each share of company common stock.
In this issue: Covid-19 has put bias in oximetry back in the spotlight, DCTs are helping break down barriers in…
ByThe company’s fourth quarter worldwide revenue declined by 1% on a reported basis to $8.09bn.
Avanos Medical recalled Cortrak* 2 EAS following reports of injuries and patient deaths due to tube misplacements.
The deal adds Intersect ENT's PROPEL and SINUVA sinus implant product lines and technology to Medtronic's portfolio.
Xpert Xpress CoV-2 plus is a rapid molecular diagnostic test designed to identify Covid-19 causing virus.
The company’s net income in the quarter jumped 51.7% Y-o-Y to $454m.
In the same quarter a year ago, the company reported revenues of $375.3m.
Thank you for subscribing to Medical Device Network